Clinical Trials Logo

Clinical Trial Summary

This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study was to test the safety and efficacy of a study drug called asfotase alfa (human recombinant tissue non-specific alkaline phosphate fusion protein) to see what effects it has on patients 5 years of age or less with HPP.

Clinical Trial Description

Asfotase alfa was formerly referred to as ENB-0040

Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease characterized by defective bone mineralization and impaired phosphate and calcium regulation that can lead to progressive damage to multiple vital organs, including destruction and deformity of bones, profound muscle weakness, seizures, impaired renal function, and respiratory failure. There are limited data available on the natural course of this disease over time, particularly in patients with the juvenile-onset form. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT01176266
Study type Interventional
Source Alexion Pharma GmbH
Status Completed
Phase Phase 2/Phase 3
Start date July 2010
Completion date September 2016

See also
  Status Clinical Trial Phase
Recruiting NCT02237625 - Natural History Study of Patients With Hypophosphatasia (HPP) N/A
Completed NCT02291497 - Burden of Disease in Hypophosphatasia (HPP) N/A
Recruiting NCT02796885 - Characterisation of Adult-Onset Hypophosphatasia
Recruiting NCT02751801 - Health Burden of Hypophosphatasia N/A
Recruiting NCT02603042 - Biomarker for Hypophosphatasia Disease
Completed NCT02797821 - Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP) Phase 2
Completed NCT01163149 - Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) Phase 2
Not yet recruiting NCT03418389 - Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia
Completed NCT02531867 - Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan Phase 4
Completed NCT01406977 - Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) Phase 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford N/A
Withdrawn NCT00894075 - Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) Phase 2
Enrolling by invitation NCT02456038 - Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP) Phase 2
Completed NCT02235493 - Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09 N/A
Completed NCT01205152 - Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) Phase 2
Approved for marketing NCT02496689 - Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP) N/A